CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has led to profound and durable tumor responses in a relevant subset of patients with relapsed/refractory (r/r) B-cell lymphomas. Still, some patients show insufficient benefit or relapse after CAR T-cell therapy. We performed a retrospective study to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wittibschlager, Valerie, Bacher, Ulrike, Seipel, Katja, Porret, Naomi, Wiedemann, Gertrud, Haslebacher, Claudia, Hoffmann, Michèle, Daskalakis, Michael, Akhoundova, Dilara, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056741/
https://www.ncbi.nlm.nih.gov/pubmed/36982764
http://dx.doi.org/10.3390/ijms24065688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056741/
https://www.ncbi.nlm.nih.gov/pubmed/36982764
http://dx.doi.org/10.3390/ijms24065688

Ejemplares similares